🇺🇸 FDA
Pipeline program

ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine

ARCT-154-01

Phase 3 mab completed

Quick answer

ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine for COVID-19 Vaccines is a Phase 3 program (mab) at Arcturus Therapeutics Holdings with 1 ClinicalTrials.gov record(s).

Program details

Company
Arcturus Therapeutics Holdings
Indication
COVID-19 Vaccines
Phase
Phase 3
Modality
mab
Status
completed

Clinical trials